Entacapone (ETP) is a catechol-O-methyltransferase
(COMT) drug used to treat Parkinson’s disease. ETP is available
in the marketplace under the brand name Comtan since 2010, and ETP
form-I was first reported in a patent published in 2001. However,
analysis of its X-ray crystal structures and stability relationship
of ETP polymorphs and their dissolution and permeability profile have
not yet been reported. We crystallized
two new conformational polymorphs of ETP from a water and acetone
mixture and studied the structural origin of polymorphism and their
phase transformations, stability, equilibrium solubility, dissolution,
and permeability properties. The ETP molecule adopts different conformations
in the polymorphic structures with slight changes in carbonyl and
nitrile group orientations. Thermal analysis suggests that form-III
and form-IV are enantiotropically related to form-I, which is the
thermodynamically stable form at ambient conditions. In contrast,
form-II is monotropically related to form-I. Equilibrium solubility,
dissolution, and permeability studies show that form-II persists in
the slurry medium and dissolves faster with a high flux rate compared
to the stable form-I in phosphate buffer solution at 37 ± 0.5
°C.